Intensity Therapeutics, Inc. Common stock (INTS) Stock Price, News & Analysis

Company Overview

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

Key Stats

• Today's Range: $2.36 to $2.79
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 73,559 shs
• Average Volume: 44,505 shs
• Market Capitalization: $34.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Buy

Intensity Therapeutics, Inc. Common stock Stock Analysis - MarketRank™

Intensity Therapeutics, Inc. Common stock scored higher than 46% of companies evaluated by MarketBeat, and ranked 513th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Intensity Therapeutics, Inc. Common stock has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Intensity Therapeutics, Inc. Common stock has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Intensity Therapeutics, Inc. Common stock are expected to grow in the coming year, from ($1.18) to ($1.00) per share.

Price to Book Value per Share Ratio

Intensity Therapeutics, Inc. Common stock has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.78% of the float of Intensity Therapeutics, Inc. Common stock has been sold short.

Short Interest Ratio / Days to Cover

Intensity Therapeutics, Inc. Common stock has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Intensity Therapeutics, Inc. Common stock has recently increased by 52.70%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Intensity Therapeutics, Inc. Common stock does not currently pay a dividend.

Dividend Growth

Intensity Therapeutics, Inc. Common stock does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.78% of the float of Intensity Therapeutics, Inc. Common stock has been sold short.

Short Interest Ratio / Days to Cover

Intensity Therapeutics, Inc. Common stock has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Intensity Therapeutics, Inc. Common stock has recently increased by 52.70%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: 1.89

News Coverage This Week

MarketBeat has tracked 3 news articles for Intensity Therapeutics, Inc. Common stock this week, compared to 0 articles on an average week.

Search Interest

3 people have searched for INTS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Intensity Therapeutics, Inc. Common stock insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.60% of the stock of Intensity Therapeutics, Inc. Common stock is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 3.74% of the stock of Intensity Therapeutics, Inc. Common stock is held by institutions.

INTS Stock Analysis - Frequently Asked Questions

How were Intensity Therapeutics, Inc. Common stock's earnings last quarter?

Intensity Therapeutics, Inc. Common stock (NASDAQ:INTS) released its quarterly earnings data on Friday, August, 9th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.04.

When did Intensity Therapeutics, Inc. Common stock IPO?

Intensity Therapeutics, Inc. Common stock (INTS) raised $20 million in an initial public offering on Friday, June 30th 2023. The company issued 3,900,000 shares at a price of $5.00 per share.

Who are Intensity Therapeutics, Inc. Common stock's major shareholders?

Top institutional shareholders of Intensity Therapeutics, Inc. Common stock include Sapient Capital LLC (6.24%).

What other stocks do shareholders of Intensity Therapeutics, Inc. Common stock own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Intensity Therapeutics, Inc. Common stock investors own include Amgen (AMGN), Costco Wholesale (COST), Cisco Systems (CSCO), Honeywell International (HON), Intel (INTC), Intuitive Surgical (ISRG) and Mondelez International (MDLZ).

Company Calendar

• Last Earnings: 8/09/2024
• Today: 1/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:INTS
• CUSIP: N/A
• CIK: 1567264
• Web: www.intensitytherapeutics.com
• Phone: 203 221 7381
• Fax: N/A
• Employees: 2,021
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.50
• High Stock Price Target: $12.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +274.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-10,540,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -209.73%
• Return on Assets: -149.19%

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 1.63
• Quick Ratio: 1.63

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.96 per share
• Price / Book: 2.36

Miscellaneous

• Outstanding Shares: 15,100,000
• Free Float: 12,295,000
• Market Cap: $34.28 million
• Optionable: Not Optionable
• Beta: 3.98